Research Article
Risk Factors for Granulocytopenia in Patients with Graves’ Disease Receiving Antithyroid Drugs
Table 1
Univariate analysis of factors for granulocytopenia induced by antithyroid drugs.
| | Variables included | Observation group (n, %) | Control group (n, %) | value |
| | Gender (female) | 70 (73.7) | 442 (61.2) | 0.017 | | WBC (×109/L) | 4.6 (3.90–6.00) | 5.90 (5.00–7.40) | <0.001 | | NLR | 0.89 (0.76–1.13) | 2.05 (1.50–3.09) | <0.001 | | ALT ≥40 (IU/L) | 34 (36.2) | 128 (18.2) | <0.001 | | AST ≥40 (IU/L) | 20 (21.1) | 74 (10.5) | 0.003 | | FT3 (pmol/L) | 17.50 (9.02–30.13) | 8.13 (4.66–15.78) | <0.001 | | FT4 (pmol/L) | 0.01 (0.01-0.01) | 0.01 (0.01–0.42) | <0.001 | | TSH (mIU/L) | 0.01 (0.01-0.01) | 0.01 (0.01–0.42) | <0.001 |
|
|
WBC: white blood cell counts, NLR: neutrophil-to-lymphocyte ratio, ALT: alanine aminotransferase, AST: aspartate aminotransferase, FT3: free triiodothyronine, FT4: free thyroxine, and TSH: thyroid stimulating hormone.
|
